GH Research PLC (NASDAQ: GHRS) released its financial results for the full year ended December 31, 2022, revealing R&D expenses were $20.5 million, a 138% increase compared to $8.6 million for the full year 2021. The increase was primarily due to increased activities relating to our technical development, clinical trials and increased employee expenses to support these activities.

Full Year 2022 Financial Highlights

Full story available on